Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2′ ,3 ′ -dideoxycytidine

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 4, 1996, Pages 953-957

  Medlin, Holly K ^a   Zhu, Ya Qi ^a   Remington, Kathryn M ^a   Phillips, Tom R ^b   North, Thomas W ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DIDANOSINE; FOSCARNET; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CAT; DRUG RESISTANCE; FELINE IMMUNODEFICIENCY VIRUS; KIDNEY CELL; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CATS; CELL LINE; DIDANOSINE; DRUG RESISTANCE, MICROBIAL; IMMUNODEFICIENCY VIRUS, FELINE; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE;

EID: 0029865203     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.4.953     Document Type: Article

References (42)

1. Ackley, C. D., J. K. Yamamoto, N. Levy, N. C. Pedersen, and M. D. Cooper. 1990. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus J. Virol. 64:5652-5655.
2. Barlough, J. E., C. D. Ackley, J. W. George, N. Levy, R. Acevedo, P. F. Moore, B. A. Rideout, M. D, Cooper, and N. C. Pedersen. 1991. Acquired immune dysfunction an cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections J Acquired Immune Defic. Syndr. 4:219-227
3. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
4. Condra, J. H., W. A. Schieif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
5. Cronn, R. C., K. M. Remington, B. D. Preston, and T. W. North. 1992 Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′-deoxyadenosine-5′-triphosphate. Biochem. Pharmacol. 44:1375-1381.
6. DeClercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
7. English, R. V., P. Nelson, C. M. Johnson, M. Nasisse, W. A. Tompkins, and M. B. Tompkins. 1994. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus. J. Infect. Dis. 170:543-552.
8. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke. and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157
9. Gao, Q., Z. Gu, J. Hiseott, G. Dionne. and M. A, Wainberg. 1993. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:130-133.
10. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19
11. Gobert, J. M., K. M. Remington, Y.-Q. Zhu, and T. W. North. 1994. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 38:861-864.
12. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
13. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg, 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
14. Hughes, S. H. Personal communication.
15. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3 0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci USA 90:6320-6324.
16. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995 Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
17. Kaplan, A. H., S. F. Michael, R. S. Wehbie, M. F. Knigge, D. A. Paul, L. Everit, D. J. Kempf, D. W. Norbeck, J. W. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl. Acad. Sci. USA 91:5597-5601.
18. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256:1783-1790.
19. Larder, B. A., K. E. Coates, and S. D. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
20. Larder, B. A., G. Darby, and D. D. Richman. 1989 HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
21. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
22. Larder, B. A., S. D. Kemp, and D. J. M. Purifoy. 1989. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 86:4803-4807.
23. North, T. W., R. C. Cronn, K. M. Remington, and R. T. Tandberg. 1990. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob. Agents Chemother. 34:1505-1507.
24. North, T. W., R. C. Cronn, K. M. Remington, R. T. Tandberg, and R. C. Judd. 1990. Characterization of reverse transcripiase from feline immunodeficiency virus. J. Biol. Chem. 265:5121-5128.
25. North, T. W., G. L. Hansen, Y.-Q. Zhu, J. A. Griffin, and C.-K, Shin. 1994. Expression of reverse transcriptase from feline immunodeficiency virus in Escherichia coli. Antimicrob. Agents Chemother. 38:388-391.
26. North, T. W., G. L. T. North, and N. C. Pedersen. 1989. Feline immunodeficiency virus: a mode! for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob. Agents Chemother. 33: 915-919.
27. Olmsted, R, A., V. M. Hirsch, R. H. Purcell, and P. R. Johnson. 1989. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc. Natl. Acad. Sci. USA 86:8088-8092.
28. Otto, M. J., S. Garber, D. L. Winslow, C. D. Reid, P. Aldrich, P. K. Jadhav, C. E. Pattersen, C. N. Hodge, and Y.-S. E. Cheng. 1993 In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90:7543-7547.
29. Pedersen, N. C. 1993 The feline immunodeficiency virus, p. 181-219. In J. A. Levy (ed.), The retroviridae, vol. 2. Plenum Press, New York
30. Pedersen, N. C., E. W. Ho, M. L. Brown, and J. K. Yamamoto. 1987. Isolation of a T-lymphotrophic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790-793.
31. Phillips, T. R., O. Prospero-Garcia, D. L. Puaoi, D. L. Lerner, H. S. Fox, R. A. Olmsted, F. E. Bloom, S. J. Henriksen, and J. H. Elder. 1994. Neurological abnormalities associated with feline immunodeficiency virus infection. J. Gen. Virol. 75:979-987.
32. Podel, M. N., M. Oglesbee, L. Mathes, S. Krakowka, R. Olmstead, and L. Lafredo. 1993. AIDS-associated encephalopathy with experimental feline immunodeficiency virus infection. J. Acquired Immune Defic Syndr. 6:758-771
33. Remington, K. M., B. Chesebro, K. Wehrly, N. C. Pedersen, and T. W. North. 1991. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J. Virol. 65:308-312.
34. Remington, K. M., Y-Q. Zhu, T. R. Phillips, and T. W. North. 1994. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J. Virol. 68:632-637.
35. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents Antimicrob. Agents Chemother. 37: 1207-1213.
36. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C. K. Shih, M. Myers, and J. Griffin. 1992. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
37. Schinazi, R., B. Larder, and J. Mellors. 1994. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance Int. Antivir News 2:72-75
38. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Ficus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations J. Infect. Dis 169:722-729.
39. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M, C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991 Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
40. Talbott, R. L., E. E. Sparger, K. M. Lovelace, W. M. Fitch, N. C. Pedersen, P. A. Luciw, and J. H. Elder. 1989. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl. Acad. Sci. USA 86:5743-5747.
41. Wainberg, M. A., Z. Gu, Q. Gao, E. Arts, R. Geleziunas, S. Bour, R. Beaulieu, C. Tsoukas, J. Singer, and J. Montaner. 1993. Clinical correlates and molecular basis of HIV drug resistance. J. Acquired Immune Defic. Syndr. 6(Suppl 1):S36-S46.
42. Yamamoto, J. K., E. Sparger, E. W. Ho, P. R. Andersen, T. P. O'Connor, C. P. Mandell, L. Lowenstine, R. Munn, and N. C. Pedersen. 1988 Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats Am. J. Vet. Res. 49:1246-1258.